Investment Rating - The investment rating for the company is "Buy-A" with a target price of HKD 16.59, maintaining the rating [5]. Core Insights - The company reported a revenue of CNY 11.799 billion for 2024, a year-on-year increase of 5.32%, while the net profit attributable to shareholders was CNY 1.303 billion, a decrease of 20.80% [1]. - The company is focusing on expanding its HNB (Heated Not Burned) product line as a second growth curve, with positive trial results for the new product glo Hilo [4][10]. - The company has increased its R&D investment to CNY 1.572 billion in 2024, a year-on-year growth of 41.30%, indicating a commitment to diversifying into nebulization technology and medical applications [4]. Revenue Performance - In 2024, the company's self-owned brand revenue grew by 34.00% to CNY 2.475 billion, accounting for 21.00% of total revenue [2]. - The revenue from enterprise clients was CNY 9.324 billion, a slight decrease of 0.30%, but showed a recovery trend with a 9.70% increase in H2 2024 [3]. - The company achieved revenue of CNY 6.762 billion in H2 2024, reflecting an 11.22% year-on-year increase [1]. Market Performance - The company experienced a strong recovery in the European and American markets, with revenues of CNY 4.24 billion and CNY 20.24 billion respectively, representing year-on-year growth of 14.00% and 37.20% [2]. - In H2 2024, the revenue from the U.S. and European markets was CNY 2.27 billion and CNY 10.95 billion, with growth rates of 8.83% and 11.61% respectively [2]. Profitability Analysis - The gross profit margin for 2024 was 37.39%, a decrease of 1.36 percentage points year-on-year, primarily due to changes in product mix [9]. - The adjusted net profit margin for 2024 was 11.04%, down 3.69 percentage points year-on-year, with H2 2024 adjusted net profit margin at 9.17%, a decline of 6.18 percentage points [9]. Future Projections - Revenue projections for 2025-2027 are CNY 12.823 billion, CNY 14.475 billion, and CNY 16.878 billion, with year-on-year growth rates of 8.68%, 12.88%, and 16.60% respectively [10]. - Net profit projections for the same period are CNY 1.476 billion, CNY 1.809 billion, and CNY 2.242 billion, with growth rates of 13.31%, 22.49%, and 23.94% respectively [10].

Investment Rating - The report maintains an "Outperform the Market" rating for the company [5] Core Insights - The company achieved a revenue of HKD 11.8 billion in 2024, representing a slight increase of 5.3%, while net profit decreased by 20.8% to HKD 1.3 billion. The second half of 2024 showed improved performance with revenue of HKD 6.76 billion, up 11.2%, and net profit of HKD 620 million, down 33.2% [1][2] - The company's proprietary brand business, including Vaporesso and MOYAL, saw significant growth, with revenue reaching HKD 2.48 billion, a 34.0% increase, and its revenue share rising from 16.5% to 21.0% [1] - The company is focusing on developing a heating not burning (HNB) product line, which is expected to become a second growth curve, with positive consumer feedback from its recent launch in Serbia [3] Summary by Sections Financial Performance - In 2024, the company reported a revenue of HKD 11.8 billion, a 5.3% increase, and a net profit of HKD 1.3 billion, a decrease of 20.8%. The second half of 2024 showed a revenue increase of 11.2% to HKD 6.76 billion, while net profit decreased by 33.2% to HKD 620 million [1][2] - The company declared a final dividend of HKD 0.05 per share, with an annual dividend yield of 40.2% [1] Business Segments - The ODM business saw a slight decline in revenue to HKD 9.32 billion, with a first half decrease of 12.3% and a second half increase of 10.7%. The European market contributed HKD 5.1 billion, while the US market generated HKD 3.99 billion [2] - The proprietary brand segment showed strong growth, particularly in Europe and other markets, with revenue of HKD 2.02 billion, a 37.2% increase, and in the US, revenue reached HKD 420 million, a 14.0% increase [1] Future Outlook - The company is optimistic about the HNB product line, which is expected to contribute to revenue growth in 2025. The focus on creating a comprehensive vaporization technology platform is anticipated to drive long-term growth [3] - The profit forecast for 2025-2027 has been adjusted, with expected net profits of HKD 1.52 billion, HKD 2.00 billion, and HKD 2.52 billion, reflecting growth rates of 16.3%, 32.0%, and 26.0% respectively [3][4]

Investment Rating - The investment rating for the company is "Buy" and is maintained [6]. Core Views - The company reported a revenue of 11.799 billion and a net profit of 1.303 billion for 2024, reflecting a year-on-year change of +5% and -21% respectively. In the second half of 2024, revenue and net profit were 6.761 billion and 620 million, showing a year-on-year increase of +11% and a decrease of -33% respectively [2][4]. - The core business of the company is recovering growth, with the HNB (Heated Not Burned) segment showing potential as a future growth driver. The company has received positive feedback from consumers and British American Tobacco in Serbia [6][4]. - The company is focusing on expanding its product matrix with new launches and enhancing its market share in the open product segment through its brand VAPORESSO [6][4]. Revenue Summary - The company's revenue from the TOB (Business to Business) segment in the second half of 2024 increased by 11%, with contributions from various regions: +5% from the US, +17% from mainland China, and +14% from Europe and other regions. The revenue breakdown shows a decline in disposable products but growth in the HNB and APV (Advanced Personal Vaporizer) segments [6][4]. - The TOC (Business to Consumer) segment also saw a revenue increase of 13% in the second half of 2024, supported by the establishment of localized marketing teams and online store management systems [6][4]. Profitability Summary - The company's gross margin decreased by 3.9 percentage points to 37.0% in the second half of 2024, primarily due to changes in product sales structure. The net profit dropped by 33%, influenced by increased sales and R&D expenses [6][4]. - The company is investing heavily in marketing and R&D, particularly in the fields of medical vaporization and heated not burned products, which is expected to impact profitability in the short term but may yield long-term benefits [6][4]. Long-term Outlook - The company aims for a market capitalization target of 300 to 500 billion, with significant growth potential in the HNB business and a positive trend in traditional business recovery. The company is committed to long-term development and increasing investment in HNB and medical vaporization R&D [6][4]. - The company has launched the Glo Hilo product in collaboration with British American Tobacco, which has shown promising feedback in terms of heating time, taste, and design, indicating a competitive edge against existing products like IQOS [6][4]. - The company is also progressing in the clinical development of drug-device combination products for respiratory diseases, which is expected to contribute significantly to revenue in the future [6][4].

Investment Rating - The investment rating for the company is "Buy" (maintained) [1][10]. Core Views - The report highlights a turning point in the company's atomization business and expresses optimism about the future of its HNB (Heated Not Burned) business [1]. - The company reported a total revenue of 11.8 billion RMB for 2024, representing a year-on-year increase of 5.3%. However, net profit decreased by 20.8% to 1.3 billion RMB, with a net profit margin of 11.0% [4][6]. Summary by Sections Financial Performance - In 2024, the company's revenue was 11.8 billion RMB, with a gross margin of 37.4%, down 1.3 percentage points from the previous year. The net profit was 1.3 billion RMB, reflecting a decrease of 20.8% year-on-year [4][6][7]. - The company declared a final dividend of 0.05 HKD per share as of December 31, 2024 [4]. Revenue Breakdown - The self-owned brand business saw significant growth, with revenue reaching 2.48 billion RMB, up 34.0% year-on-year. Notably, revenue from Europe and other regions for electronic atomization products was 2.02 billion RMB, up 37.2% [6]. - Revenue from enterprise client business was 9.32 billion RMB, slightly down by 0.3%. The report anticipates that increased regulatory enforcement in the U.S. will enhance market share for compliant products [6]. Research and Development - The company maintained a high R&D expenditure, amounting to 1.57 billion RMB, which is 13.3% of total revenue. This includes 1.03 billion RMB for electronic nicotine delivery systems [6][7]. - Sales and distribution expenses rose significantly by 74.7% to 920 million RMB, attributed to increased marketing efforts for self-owned brands globally [6]. Future Projections - The company is projected to achieve revenues of 13.13 billion RMB in 2025, 15.27 billion RMB in 2026, and 17.54 billion RMB in 2027, with growth rates of 11%, 16%, and 15% respectively [9][10]. - Expected net profits for 2025, 2026, and 2027 are 1.63 billion RMB, 2.15 billion RMB, and 2.64 billion RMB, with growth rates of 25%, 32%, and 23% respectively [9][10].

Investment Rating - The investment rating for the company is "Buy" [2] Core Insights - The company's performance in Q4 2024 met expectations, with revenue of HKD 11.8 billion, a year-on-year increase of 6%, and a net profit of HKD 1.3 billion, a year-on-year decrease of 21% [9] - The decline in net profit is attributed to a 1.3 percentage point drop in gross margin due to changes in product mix and a 3.1 percentage point increase in sales expense ratio due to increased marketing investments in proprietary brands [9] - The company is focusing on long-term strategies, continuous R&D investments, and strengthening its technological moat while binding with international leading clients [9] Financial Summary - Revenue and profit figures for the company from 2021 to 2027 are as follows: - Revenue: HKD 13,755 million (2021), HKD 12,157 million (2022), HKD 11,177 million (2023), HKD 11,799 million (2024), projected HKD 12,423.9 million (2025E), HKD 14,311 million (2026E), HKD 16,699 million (2027E) [7] - Net Profit: HKD 5,287 million (2021), HKD 2,510 million (2022), HKD 1,645 million (2023), HKD 1,303 million (2024), projected HKD 1,300 million (2025E), HKD 1,653 million (2026E), HKD 2,178 million (2027E) [7] - The company’s PE ratio is projected to be 58.0 (2024E), 46.0 (2025E), and 34.7 (2026E) [7] Business Segments - The company's OEM business showed positive growth in H2 2024, with revenue increasing by 11% year-on-year, particularly in the U.S. market, which saw a 5% increase [9] - The proprietary brand segment continued to grow, with an 11% year-on-year increase in revenue in H2 2024, driven by product line expansion and enhanced brand recognition in the U.S. and U.K. markets [9]

Investment Rating - The investment rating for the company is "Buy" with a target price set at a significant upside potential [4][3]. Core Insights - The company reported a revenue of 11.8 billion HKD for 2024, reflecting a year-on-year growth of 5.3%, while net profit decreased by 20.8% to 1.303 billion HKD [1]. - The company maintains its position as a global leader in the manufacturing of vaporization devices, with a notable increase in its proprietary brand business [2]. - The company is expected to benefit from the tightening regulations in the industry, leading to increased concentration within the supply chain [3]. Summary by Sections Financial Performance - Revenue from enterprise customer business reached 9.324 billion HKD, accounting for 79.0% of total revenue, with a slight decline of 0.3% year-on-year. However, the second half of 2024 saw a recovery with a revenue of 5.357 billion HKD, up by 9.7% [7]. - The company’s proprietary brand business generated 2.475 billion HKD, representing 21.0% of total revenue and a growth of 34% year-on-year [7]. - The gross margin for 2024 was 37.4%, a decrease of 1.3 percentage points, primarily due to changes in product mix [7]. Market Position and Growth - The company holds a market share of approximately 13.1% in the electronic vaporization device sector, maintaining its status as the largest manufacturer globally [7]. - The company’s proprietary brand "VAPORESSO" has seen an increase in market share within the open product market, contributing to overall growth [7]. Research and Development - R&D expenditure for 2024 was 1.572 billion HKD, a 6.0% increase year-on-year, representing 13.3% of total revenue. This investment is focused on vaporization medical products and heated non-combustible products [7].

Investment Rating - The report does not provide a specific investment rating for the company [1] Core Views - The company reported a total revenue of 11.799 billion yuan for 2024, representing a year-on-year increase of 5.6%, while net profit decreased by 20.8% to 1.303 billion yuan [1][2] - The growth in revenue is attributed to strong momentum in APV and cartridge replacement repairs, although profits are under pressure due to increased short-term expenses [1][2] - The company’s APV segment achieved revenue of 2.475 billion yuan in 2024, a significant year-on-year increase of 34.0%, with notable growth in Europe and the US [2][3] - The HNB product line has made significant progress, with successful product launches and positive feedback from customers, positioning HNB as a key growth area for the company [3][4] Summary by Sections Financial Performance - In 2024, the company achieved total revenue of 11.799 billion yuan, with a net profit of 1.303 billion yuan, reflecting a decrease of 20.8% year-on-year [1][7] - The gross margin for 2024 was 37.4%, down 1.4 percentage points from the previous year, while the net profit margin was 12.01%, a decrease of 2.0 percentage points [5][9] - The company expects net profits for 2025-2027 to be 1.547 billion yuan, 2.420 billion yuan, and 3.077 billion yuan respectively, with corresponding P/E ratios of 49.4X, 31.6X, and 24.9X [5][7] Revenue Breakdown - The APV segment's revenue for 2024 was 2.475 billion yuan, with growth rates of 34.0% year-on-year, and the second half of the year saw a revenue of 1.359 billion yuan, up 13.4% year-on-year [2][3] - The OEM business generated revenue of 9.224 billion yuan in 2024, a slight decrease of 0.3% year-on-year, but showed a recovery in the second half with a 10.7% increase [2][3] Future Outlook - The company is focusing on HNB as a second growth curve, with plans for a key rollout in 2025 across multiple global markets [3][4] - The company is also investing in R&D and seeking collaborations with industry leaders to enhance its HNB offerings [3][4]

Investment Rating - The report does not provide a specific investment rating for the company [1] Core Views - The company has shown a steady revenue growth of 5.6% year-on-year, achieving a total revenue of 11.799 billion yuan in 2024, although net profit decreased by 20.8% to 1.303 billion yuan due to increased short-term expenses [1][2] - The company's APV segment has performed well, with a revenue increase of 34.0% year-on-year, reaching 2.475 billion yuan, driven by strong growth in Europe and the US [2] - The HNB product line has made significant progress, with plans for a broader market launch in 2025, indicating potential for future revenue growth [3] Summary by Sections Financial Performance - In 2024, the company reported total revenue of 11.799 billion yuan, with a year-on-year growth of 5.6%. The net profit was 1.303 billion yuan, down 20.8% from the previous year [1][5] - The gross margin for 2024 was 37.4%, a decrease of 1.4 percentage points year-on-year, while the net profit margin was 12.01%, down 2.0 percentage points [5] Revenue Breakdown - The APV segment generated 2.475 billion yuan in revenue, marking a 34.0% increase year-on-year, with notable growth in Europe (+37.2%) and the US (+14.0%) [2] - The OEM business saw a slight decline of 0.3% year-on-year, totaling 9.224 billion yuan, but showed a recovery in the second half of the year with a 10.7% increase [2][3] Future Outlook - The company is focusing on HNB as a key growth area, with innovative product designs and positive feedback from customers, aiming for a significant market presence by 2025 [3] - The forecast for net profit from 2025 to 2027 is projected to grow to 1.547 billion yuan, 2.420 billion yuan, and 3.077 billion yuan respectively, with corresponding P/E ratios decreasing from 49.4X to 24.9X [5][7]

Investment Rating - The investment rating for the company is "Buy" with a target price set above the current price of 13.3 HKD, indicating an expected return of over 20% within the next six months [4][12]. Core Views - The company reported a revenue of 11.8 billion HKD for 2024, reflecting a year-on-year growth of 5.3%, while net profit decreased by 20.8% to 1.303 billion HKD [1][3]. - The company maintains its position as a global leader in the manufacturing of vaporization devices, with a market share of approximately 13.1% [7]. - The self-branded business segment showed significant growth, achieving a revenue of 2.475 billion HKD, which is a 34% increase year-on-year [7]. Summary by Sections Financial Performance - In 2024, the company generated 9.324 billion HKD from enterprise client business, accounting for 79.0% of total revenue, with a slight decline of 0.3% year-on-year. However, the second half of 2024 saw a recovery with a revenue of 5.357 billion HKD, up 9.7% [7]. - The company’s gross margin for 2024 was 37.4%, a decrease of 1.3 percentage points, primarily due to changes in product mix [7]. Business Segments - The enterprise client business saw revenues of 5.096 billion HKD from Europe and other markets, a slight increase of 0.3% year-on-year, while the U.S. market generated 3.988 billion HKD, down 2.4% [7]. - The self-branded business, including the newly launched "Lan Zhi" beauty vaporization product, contributed 2.475 billion HKD, with a notable growth of 34% [7]. Research and Development - The company invested 1.572 billion HKD in R&D in 2024, representing 13.3% of revenue, which is a 6.0% increase year-on-year [7]. - The focus of R&D includes products for vaporization medical applications and heated non-combustible products, with positive feedback received from consumers [7].

Core Viewpoint - Smoore International (06969) experienced a decline of over 6% in stock price, attributed to short-term pressure on profitability despite a revenue increase in the latest financial report [1] Financial Performance - For the fiscal year 2024, Smoore reported revenue of 11.799 billion RMB, reflecting a year-on-year increase of 5.3% [1] - The company's net profit was 1.303 billion RMB, showing a year-on-year decline of 20.8% [1] - Basic earnings per share were 21.42 cents, with a proposed final dividend of 0.05 HKD per share [1] Market and Product Outlook - The chairman and CEO, Chen Zhiping, indicated that the company's support for clients in launching heated not-burn (HNB) products will lead to increased sales in more global markets starting mid-year [1] - Although HNB products are not expected to contribute significantly to profits this year and may even incur losses, they are projected to provide substantial profit contributions starting next year, potentially exceeding those from e-cigarettes in the long term [1]